Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer.

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer.

As ACE2 is the critical SARS-CoV-2 receptor, we hypothesized that aerosol administration of clinical grade soluble human recombinant ACE2 (APN01) will neutralize SARS-CoV-2 in the airways, limit spread of infection in the lung, and mitigate lung damage caused by deregulated signaling in the renin-an...

Full description

Saved in:
Bibliographic Details
Main Authors: Robert H Shoemaker, Reynold A Panettieri, Steven K Libutti, Howard S Hochster, Norman R Watts, Paul T Wingfield, Philipp Starkl, Lisabeth Pimenov, Riem Gawish, Anastasiya Hladik, Sylvia Knapp, Daniel Boring, Jonathan M White, Quentin Lawrence, Jeremy Boone, Jason D Marshall, Rebecca L Matthews, Brian D Cholewa, Jeffrey W Richig, Ben T Chen, David L McCormick, Romana Gugensberger, Sonja Höller, Josef M Penninger, Gerald Wirnsberger
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0271066&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0271066&type=printable

Similar Items